Overview

* Axsome Q2 2025 net product revenue grows 72% yr/yr to $150 mln

* AUVELITY sales increase 84% yr/yr, driving revenue growth

* Net loss narrows to $48 mln from $79.3 mln in prior year

Outlook

* Axsome plans AXS-05 sNDA submission for Alzheimer's agitation in 3Q 2025

* Company expects AXS-12 NDA submission for narcolepsy in 4Q 2025

* Axsome to initiate Phase 3 trials for solriamfetol in ADHD, MDD in 4Q 2025

* Company confident current cash will fund operations to cash flow positivity

Result Drivers

* AUVELITY SALES - AUVELITY sales grew 84% yr/yr to $119.6 mln, driven by expanded market access with 28 mln new covered lives

* SUNOSI GROWTH - SUNOSI sales increased 35% yr/yr to $30 mln, supported by strong prescription growth

* SYMBRAVO LAUNCH - SYMBRAVO launched in June, contributing $0.4 mln to Q2 revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.97

Q2 Net -$47.97

Income mln

Q2 $186.76

Operatin mln

g

Expenses

Q2 -$36.71

Operatin mln

g Income

Q2 -$48.93

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Axsome Therapeutics Inc ( AXSM ) is $181.50, about 43.2% above its August 1 closing price of $103.02

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)